Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, Courtney D. DiNardo

doi:HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27434

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

Authors: Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, Courtney D. DiNardo

Published: 2024-07-17

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27434

Keywords: No keywords found.

Abstract:
AbstractThe advent of molecularly targeted therapeutics has transformed the management of patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive chemotherapy, lower intensity therapies (LIT) incorporating small molecules have significantly improved patient outcomes. With BCL2, IDH1, IDH2, and FLT3 inhibitors widely used for relapsed AML, combination regimens are now utilized in the frontline. Expansion of these targeted LIT combinations, along with development of novel agents including menin inhibitors, exemplifies the promise of precision medicine. Further understanding of molecular drivers of leukemic transformation and mechanisms of relapse will continue to advance frontline treatment options for patients with AML.

Source: